SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Jun 20, 2007 -- Theravance, Inc. (NasdaqGM:THRX - News) announced today that it has enrolled the last patient in its Phase 3 clinical program with the investigational antibiotic telavancin in patients with hospital-acquired pneumonia (HAP) due to Gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). Telavancin is currently under regulatory review in both the United States and Europe for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria.
